Abstract Epoxyeicosatrienoic acids (EETs), the metabolites of arachidonic acid derived from the cytochrome P450 (CYP450) epoxygenases, are mainly metabolized by soluble epoxide hydrolase (sEH) to their corresponding diols. EETs but not their diols, have anti-inflammatory properties and inhibition of sEH might provide protective effects against inflammatory fibrosis. We test the effects of a selected sEH inhibitor, 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea (TPPU), on bleomycin-induced pulmonary fibrosis (PF) in mice. A mouse model of PF was established by intratracheal injection of bleomycin and TPPU was administered for 21 days after bleomycin injection. We found TPPU treatment improved the body weight loss and survival rate of bleomycin-stimulated mice. Histological examination showed that TPPU treatment alleviated bleomycin-induced inflammation and maintained the alveolar structure of the pulmonary tissues. TPPU also decreased the bleomycin-induced deposition of collagen and the expression of procollagen I mRNA in lung tissues of mice. TPPU decreased the transforming growth factor-β1 (TGF-β1), interleukin-1β (IL-1β) and IL-6 levels in the serum of bleomycinstimulated mice. Furthermore, TPPU inhibited the proliferation and collagen synthesis of mouse fibroblasts and partially reversed TGF-β1-induced α-smooth muscle actin expression. Our results indicate that the inhibition of sEH attenuates bleomycin-induced inflammation and collagen deposition and therefore prevents bleomycin-induced PF in a mouse model.
Introduction
Idiopathic pulmonary fibrosis (IPF) is characterized by inexorable progressive fibrosis, which involves the interstitial space that exists between the vascular endothelium and alveolar epithelium. The pathological processes of IPF include alveolar epithelial cell injury, fibroblast proliferation and abnormal deposition of extracellular collagen. Transforming growth factor-β1 (TGF-β1), an inflammatory biomarker, is one of the key mediators in the fibrotic process. TGF-β1 is involved in pulmonary inflammation, tissue repair and fibrosis (Sheppard 2006) . The differentiation of fibroblasts to myofibroblasts, with the high expression of α-smooth muscle actin (α-SMA), contributes to the formation of fibroblastic foci. IPF affects as many as 14-43 people per 100 000 worldwide (Raghu et al. 2006 ) and useful treatment is lacking. Thus, novel therapeutic agents for this unmet medical need are of particular interest.
Epoxyeicosatrienoic acids (EETs) are synthesized from arachidonic acid by cytochrome P450 (CYP) epoxygenases and function primarily as autocrine and paracrine effectors. They produce vasodilation and anti-inflammatory and profibrinolytic effects and are mostly metabolized by soluble epox ide hyd rola se ( sEH), whic h c ove rts EETs t o dihydroxyeicosatrienoic acids (DHETs; Spector et al. 2004 ). Inhibition of sEH has been shown to enhance the biological activity of EETs. The lung vasculature is known to be a rich source of lipid mediator biosynthesis from arachidonic acid and EETs have been previously described as the predominant eicosanoids in human lungs upon stimulation with the Ca 2+ ionophore A23187 (Kiss et al. 2010) . EETs in the lung are involved in many pulmonary diseases, such as asthma (Norton et al. 2012; Yang et al. 2015) , cigarette smoke extract-induced lung injury (Yu et al. 2015) , lung ischemia-reperfusion injury (Chen et al. 2015) and pulmonary hypertension (Revermann et al. 2009) . A recent study showed that EETs can inhibit the expression of α-SMA and TGF-β1/SMADs and protect the remnant kidney in the nephrectomized rat via the inhibition of fibrosis (Zhao et al. 2012) . Furthermore, inhibition of sEH prevents renal interstitial fibrosis and inflammation (Kim et al. 2014) . However, whether the inhibition of sEH can provide protective effects against pathological processes of pulmonary fibrosis (PF) is unknown.
Intratracheal administration of bleomycin (BLM) is the most extensively used experimental model of PF because the pathological features produced by this procedure are similar to those of IPF (Della Latta et al. 2015) . In the present study, we test the effect of 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea (TPPU), a potent sEH inhibitor provided by Prof. Hammock (Sirish et al. 2013 ), on BLMinduced PF. In addition, we also study the effect of TPPU on the proliferation and differentiation of mouse fibrosis and on the deposition of extracellular collagen in vitro.
Materials and methods
Animals and treatments Experimental use of mice in the present study was performed according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals and the animal protocol was approved by the institutional animal care committee. Adult male C57BL/6 mice were provided by the laboratory animal unit of Central South University. The mice were randomly divided into three groups: (1) intratracheal saline (normal group); (2) intratracheal BLM plus vehicle (BLM group); (3) intratracheal BLM plus TPPU treatment (BLM + TPPU group). The mouse model of PF was established by an intratracheal injection of BLM (5 mg/kg; Nippon Kayaku, Japan) according to a previous published protocol (W. ). All surgery was performed under anesthesia with an intraperitoneal injection of sodium pentobarbital (30 mg/kg). TPPU (1 mg/kg/day) was administered by gavage dosing after BLM injection. TPPU was dissolved in oleic-acid-rich triglyceride containing 20 % PEG400 (v/v) to give a clear solution. The mice were killed under anesthesia on day 7, 14 and 21. The additional 60 mice were used to determine the effect of TPPU on the survival rate of mice receiving BLM treatment. These mice were treated as described above. Body weight was recorded.
Histopathology analysis Lung tissue samples were fixed with 4 % paraformaldehyde in neutral buffer solution for 24 h, dehydrated in a graded ethanol series, embedded in paraffin and sliced at 5 μm. Paraffin sections were stained with hematoxylin and eosin (HE) and Masson's trichrome stain. The Ashcroft score was used for the semi-quantitative assessment of fibrotic changes (Murakami et al. 2004) . Thirty fields in each section were analyzed and the severity of fibrotic changes in each mouse was assessed as the mean of severity from observed microscopic fields.
Hydroxyproline assay The hydroxyproline content in the supernatant of cell and lung tissue was calculated according to the manufacturer's instructions for the hydroxyproline assay kit (Sigma-Aldrich, USA). The sample absorbencies were assessed at 550 nm.
Total RNA extraction and real-time polymerase chain reaction Total RNA from lung tissues was extracted by using TRIzol reagent (Invitrogen, USA) and was quantified by spectrophotometric analysis by using an ultraviolet spectrophotometer (Bio-Rad, USA). The generation of cDNA from RNA (2 μg) was performed with RevertAid reverse transcriptase (Thermo-Scientific, USA) and random hexamer primers according to the manufacturer's instructions. Real-time polymerase chain reaction (PCR) of cDNA was performed with iTaq Universal SYBR Green Supermix. The sequences of the specific primers are shown in Table 1 . Relative gene expression was measured by the 2 -ΔΔCT method and was normalized to β-actin mRNA levels.
Measurement of cytokine levels in serum by enzymelinked immunosorbent assay The serum concentrations of pro-fibrogenic cytokine (TGF-β1) and pro-inflammatory cytokines (interleukin-1β and IL-6) were measured by using the commercially available enzyme-linked immunosorbent assay (ELISA) kit (Sigma, USA), according to the manufacturer's instructions.
MTT assay The fibroblast cells (NIH3T3, ATCC Number CRL-1658) were seeded in a 96-well cell culture plate and w e r e i n c u b a t e d w i t h T P P U ( 0 . 1 , 1, 10 μ M) or dimethylsulfoxide (DMSO; 0.1 %) for 12, 24, or 36 h at 37°C. An aliquot of 20 μl of 3-(4,5-dimethyl-thiazolyl-2)-2, 5-diphenol tetrazolium bromide (MTT) solution (5 mg/ml, Sigma-Aldrich, USA) was added to each well, followed by incubation at 37°C for an additional 4 h. The supernatant was gently removed and 100 μl DMSO was added. The culture plate was shaken for 10 min at room temperature. The absorbance was measured at 492 nm.
Lactate dehydrogenase activity assay Mouse fibroblast cells (NIH3T3) were plated into 12-well plates and serum-starved for 1 day. The cells were divided into three groups treated with various concentrations of TPPU (0.1, 1, 10 μM) and a DMSO (0.1 %) vehicle group. TPPU or DMSO was added to the four groups, respectively and after 48 h, the medium was collected for the measurement of lactate dehydrogenase (LDH) activity. LDH activity was determined by using a Sigma Tox-7 in vitro toxicology kit and reported as the amount of LDH activity in the medium.
Cell cycle analysis NIH3T3 were seeded in 6-well cell culture plates. The cells were divided into six groups: normal group, DMSO vehicle group, TGF-β1 group, TGF-β1 + DMSO group and TGF-β1 + TPPU (1 and 10 μM) group. TPPU was added prior to TGF-β1 (10 ng/ml; R&D Systems, USA) treatment for 24 h. The cells were trypsinized and centrifuged at 1000 rpm for 5 min. Then, the cells were fixed with cold 70 % ethanol at 4°C overnight. The cells were resuspended in 1 ml phosphate-buffered saline containing 1000 U RNase A. The cells were stained with 1 % propidium iodide (PI) at 4°C for 30 min. DNA profiles were determined within 2 h by using a flow cytometer (Beckman Coulter MoFlo XDP, USA). Data were acquired and analyzed by using Summit v5.2 software (Beckman Coulter).
Western blot Western blot was used to detect α-SMA protein expression in mouse fibroblasts (NIH3T3). The cells were lysed with RIPA lysis buffer containing a cocktail of protease inhibitors. Total protein was determined by using a modified Bradford protein assay (Sigma-Aldrich, USA). Protein (50 μg) was fractionated on a 15 % SDS-polyacrylamide gel and transferred to polyvinylidene difluoride membranes. After being blocked for 2 h in 5 % non-fat milk in TRIS-buffered saline with Triton X-100, the membranes were incubated overnight at 4°C with either a mouse monoclonal anti-α-SMA (Sigma-Aldrich, USA) or a rabbit anti-β-actin (Cell Signaling Technology, USA) antibody (Ab). The membranes were then washed three times and incubated with the secondary Abs conjugated to horseradish peroxidase (Thermo-Scientific, USA) for 2 h at room temperature. Immunostained bands were visualized with the SuperSignalH West Pico Chemiluminescent Substrate kit (Thermo-Scientific, USA). The band intensities on scanned gels were analyzed by using the public domain National Institutes of Health ImageJ program.
Lipid mediator analysis and TPPU concentration measurements in blood The profiles of lipid mediators were measured by using the liquid chromatography/double mass spectrometry (LC/MS/MS) method as previously published (Yang et al. 2009 ). Briefly, aliquots of plasma (250 μl) were used for the measurements after the solid phase extraction protocol. The blood concentrations of TPPU were measured by LC/ MS/MS (J.Y. ). An aliquot of 10 μl blood was diluted by 50 μl water with 0.1 % EDTA and the mixtures were extracted by using 200 μl ethyl acetate twice and dried by Speedvac. Finally, the residue was reconstituted to 50 μl and measured by using LC/MS/MS (ABI, Milford, Mass., USA).
Statistical analysis All values are expressed as the means± SEM. Differences between multiple groups were compared by using one-way analysis of variance. The SNK test served as the post hoc test for multiple comparisons. Survival rate was evaluated by the Kaplan-Meier test. Significance was established at P<0.05.
Results
TPPU attenuated BLM-induced body weight loss and mortality PF is a progressive and highly devastating interstitial lung disease. In this study, we found that the body weights in the BLM group decreased during days 0-21 post BLM administration. TPPU treatment attenuated the body weight loss (P<0.05 vs. BLM group, Fig. 1a) . Furthermore, the mice challenged with BLM began dying at day 2 after BLM treatment and the mortality rate was approximately 55 % on day 14. TPPU treatment delayed the onset of death and improved the mortality rate associated with BLM (P<0.01 vs. BLM group, Fig. 1b ). For example, the mice treated with TPPU began to die on day 5, with a final mortality rate of approximately 25 % on day 14. 
TPPU attenuated BLM-induced morphological changes in mice The effect of TPPU on BLM-induced inflammation and fibrosis was examined on days 7, 14 and 21 after injection of BLM (Fig. 2) . HE staining of lung tissues from the normal group revealed a well-alveolized pulmonary structure (Fig. 2a, d, g ). BLM induced significantly alveolar wall thickening and massive infiltration of inflammatory cells in the interstitial tissue (Fig. 2b , e, h). Although lung injury was observed in the BLM + TPPU-treated group, both the extent and intensity of the injury were less than those of the BLM group (Fig. 2c , f, i).
TPPU decreased BLM-induced collagen deposition in lung tissue
Masson's trichrome stain was used to detect collagen deposition in lung tissue. Compared with the normal group, BLM treatment (5 mg/kg) significantly increased collagen deposition in lung tissue on day 14 and collagen deposition peaked on day 21. TPPU treatment (1 mg/kg per day) decreased BLM-induced collagen deposition at vaarious times ( Fig. 3a-i) . The Ashcroft score for semi-quantitative results demonstrated that the degree of PF in the BLM + TPPU group was significantly lower than in the BLM group at day 14 and day 21 (both P<0.05, Fig. 3j ). In addition, real-time PCR (Fig. 4a) showed that BLM treatment significantly increased the expression of collagen type I mRNA compared with the control group on day 21 (P<0.05). TPPU treatment substantially reduced the expression of collagen type I mRNA as compared with the BLM group (P<0.05). However, the expression of collagen type III mRNA was unchanged among the three groups (data not shown). Furthermore, TPPU treatment reduced the amount of hydroxyproline, a major component of collagen, compared with that in the BLM group (Fig. 4b, P<0 .05). These results indicated that TPPU treatment decreased the BLM-induced deposition of collagen in the lung tissue.
TPPU decreased the serum level of TGF-β1, IL-1β and IL-6 in BLM-challenged mice TGF-β1 is a pro-fibrogenic cytokine. It plays a vital role in the proliferation and differentiation of fibroblasts and in the epithelial-mesenchymal transition of pulmonary epithelial cells. We found that the concentration of TGF-β1 in BLM-challenged mice increased at day 7 and day 21 after BLM treatment (P<0.05 vs. normal group). TPPU treatment decreased the concentration of serum TGF-β1 (P<0.05 vs. BLM group, Fig. 5a, b) . IL-1β and IL-6 are pro-inflammatory cytokines. We also found that BLM treatment increased the serum concentration of IL-1β and IL-6 at day 7 and day 21 after BLM treatment (P<0.05 vs. normal group) and TPPU treatment significantly decreased the serum concentration of IL-1β and IL-6 (P<0.05 vs. BLM group, Fig. 5c-f) .
TPPU inhibited proliferation of fibroblasts in vitro
The effects of sEH inhibitor on proliferation, differentiation and collagen synthesis of fibroblasts were examined. We found that TPPU inhibited the proliferation of the fibroblasts in a time-and dose-dependent manner. A lower concentration of TPPU at 0.1 μM did not affect the proliferation of mouse fibroblasts as compared with the control group (P>0.05 vs. DMSO group). However, 1 μM TPPU treatment for 24 h and 36 h significantly reduced the proliferation of mouse fibroblasts (in both cases, P <0.05 vs. DMSO group). A higher concentration of TPPU at 10 μM significantly reduced the proliferation of mouse fibroblasts at various tested times (P<0.05 vs. DMSO group, Fig. 6a ). LDH is contained in living cells and, hence, the appearance of this enzyme in the medium is an indication that cells have died and released this protein. LDH appearance in the medium was measured and found to be unchanged in cells (Fig. 6b) demonstrating the lack of toxicity of TPPU in these cells. Next, mouse fibroblasts were stained with PI and DNA labelling was detected by using flow cytometry to analyze the cell cycle. The results showed that 1 and 10 μM TPPU significantly reduced the percentage of cells in S phase (P < 0.05 vs. DMSO + TGF-β1 group, Fig. 7) . These data Fig. 5 Effect of TPPU on BLM-induced production of pro-fibrotic and pro-inflammatory cytokines in serum. a, b Transforming growth factor-β1 (TGF-β1) concentration in serum of mice at day 7 and day 21, respectively. c, d Interleukin-1β (IL-1β) concentration in serum of mice at day 7 and day 21, respectively. e, f IL-6 concentration in serum of mice at day 7 and day 21, respectively. *P<0.05 vs. normal group, # P<0.05 vs. BLM group TPPU inhibited the differentiation of mice fibroblasts in vitro Fibroblasts can differentiate into myofibroblasts and these differentiated myofibroblasts express high levels of the α-SMA. We measured the expression of α-SMA mRNA and protein by using real-time PCR and Western blot analysis, respectively. We found that treatment with TGF-β1 (10 ng/ml) for 24 h significantly increased the expression of α-SMA mRNA and protein in mouse fibroblasts. TPPU significantly reduced the expression of α-SMA mRNA and protein in TGF-β1-treated mouse fibroblasts (Fig. 8a, b) . These findings suggested that TPPU could inhibit the differentiation of fibroblasts into myofibroblasts.
TPPU inhibited collagen synthesis of fibroblasts in vitro
An additional feature of myofibroblasts is their collagen synthesis. Therefore, we tested the effect of TPPU on the collagen synthesis of TGF-β1-stimulated mouse fibroblasts. Real-time PCR results (Fig. 8c) showed that the expression of collagen After achieving confluency, the cells were incubated with TPPU at the indicated concentrations and lactate dehydrogenase (LDH) release into the medium was measured. Representative results are shown (n=8). *P<0.05 vs. DMSO group, **P<0.05 vs. DMSO group type I mRNA was significantly increased after treatment with TGF-β1 (10 ng/ml) for 24 h. TPPU (1, 10 μM) inhibited the expression of collagen type I mRNA in a dose-dependent manner. Furthermore, we analyzed the hydroxyproline content in the supernatant. The results (Fig. 8d ) demonstrated that treatment with TPPU (1, 10 μM) significantly reduced the TGF-β1-induced hydroxyproline in the supernatant of mouse fibroblasts. These findings indicated that TPPU could inhibit TGF-β1-induced synthesis and the secretion of collagen in cultured mouse fibroblasts.
TPPU increased endogenous EETs in plasma Finally, the serum concentration of TPPU and 14,15-EET, one of the most predominated form of EETs in plasma, were measured at the end of the TPPU treatment. We found that the serum concentration of TPPU in the TPPU + BLM group (810±88 ng/ml) was significantly higher than that in the normal group (nondetected) and BLM-treated group (non-detected; P<0.05, Fig. 9a ). Treatment with TPPU significantly increased the concentration of the serum 14,15-EET (4.1±0.9 nM) as compared to following treatment with BLM only (1.8±0.6 nM) or no treatment (normal, 1.668±0.025 nM; P<0.05, Fig. 9b ). These results suggest that TPPU can inhibit EET degradation and therefore increase the concentration of serum EET.
Discussion
PF is a pathological process in which normal lung tissues are progressively replaced by fibroblasts and collagen, thereby resulting in an irreversible loss in the ability to transfer oxygen into the bloodstream via the pulmonary alveoli. The disease is characterized by fibroblastic foci-containing fibroblasts and myofibroblasts that are the primary source of extracellular matrix (ECM) components, such as collagen types I and III and fibronectin (Scotton and Chambers 2007) . Studies of the pathogenesis of PF have mainly focused on the mechanisms that regulate the proliferation, activation and differentiation of Fig. 8 Effect of TPPU on TGF-β1-induced activation of mouse fibroblast. a, b TPPU treatment inhibited TGF-β1-induced α-smooth muscle actin (α-SMA) mRNA and protein expression in mouse fibroblasts. Mouse fibroblasts were treated with TPPU (1, 10 μM) followed by TGF-β1 stimulation (10 ng/ml). (Wynn 2011) . Idiopathic PF is a particularly severe form of PF with a life expectancy of 2-6 years after diagnosis (Chaudhuri et al. 2014) . Currently, lung transplantation is the only effective treatment available for progressive lung fibrosis.
EETs are endogenous bioactive lipid mediators synthesized from arachidonic acid by a reaction catalyzed by P450 epoxygenase. Four EET regioisomers, namely 5, 8, 11, have been identified, with 11, [12] [13] [14] 15 -EET being the predominating form in the blood circulation and lung tissue (Spector et al. 2004) . EETs have various beneficial effects against inflammation, platelet aggregation and the migration of vascular smooth muscle cells , are involved in pulmonary diseases, such as pulmonary hypertension and allergic asthma and in bronchi Loot and Fleming 2011; Norton et al. 2012; Senouvo et al. 2011 ) and can be further metabolized by sEH to DHETs, which possess fewer biological activities than EETs . Therefore, the inhibition of sEH might potentiate the beneficial effects of EETs. TPPU is one of the most recently synthesized, stable, potent sEH inhibitors and has been shown to stabilize EETs in vivo (Ulu et al. 2012) . Previous studies have demonstrated that TPPU inhibits inflammatory and cardiac fibrosis through the inhibition of sEH (J.Y. Sirish et al. 2013) . In this study, we used TPPU to inhibit sEH activity and to determine whether sEH inhibition can provide protective effects against BLM-induced PF in a mouse model and cultured fibroblasts.
The BLM challenge is a well-established model of murine PF and has been used to investigate the pathophysiology of idiopathic PF. BLM is a chemotherapeutic agent that has been used for the treatment of squamous cell carcinomas, esophageal carcinoma, germ cell ovarian tumors and gestational trophoblastic neoplasms. As is well recognized, a subset of patients who receive BLM develop PF in a time-and dosedependent manner. Thus, many studies have used BLM to produce PF in animal models. A single intratracheal injection of BLM is the most prevalent stimulus that causes PF in mice and its relative simplicity makes this approach popular. In our study, we established this mouse PF model by using a single intratracheal injection of BLM. Similar to previous observations, structural damage to the lung tissue, the infiltration of inflammatory cells and obvious edema were observed 7 days after BLM injection (W. ). In addition, the Masson's trichrome staining results showed significant collagen deposition. Inhibition of sEH by TPPU treatment significantly attenuated the BLM-induced inflammation and PF as illustrated by the improvement in the morphological changes and the decrease in collagen deposition. Thus, the CYP epoxygenase pathway might be involved in the pathological process of BLM-induced PF in mouse. Furthermore, by inhibiting degradation of EETs with the sEH inhibitor, TPPU might provide a potential therapeutic approach for the treatment of IPF.
In view of the importance of fibroblast functions in the development of PF, we further explored the effect of TPPU on fibroblast function. The results of the MTT assay showed that TPPU inhibited fibroblast proliferation. The analysis by flow cytometry indicated that TPPU treatment reduced the ratio of the number of cells in S phase, which represents the percentage of cells undergoing DNA synthesis. These results suggest that TPPU inhibited the proliferation of mouse fibroblasts via the inhibition of DNA synthesis. Myofibroblasts that have differentiated from fibroblasts have contractile functions with the following histological characteristics: increased expression of α-SMA and increased collagen synthesis. TGF-β1 is one of the most potent cytokines that can induce the differentiation of fibroblasts. In our study, we found that The concentration of 14,15-EET in the TPPU + BLM group was significantly higher than that in the normal and the BLM groups (n=8). *P<0.05 vs. normal group TGF-β1 could increase the expression of α-SMA mRNA and of collagen type I mRNA and the hydroxyproline content in the cell culture supernatant. Interestingly, TPPU treatment partially reversed the changes induced by hTGF-β1-stimulation. This finding indicated that sEH inhibition reduced the differentiation and collagen synthesis of mouse fibroblasts in vitro. Furthermore, TGF-β superfamily ligands bind to the type II receptor, which recruits and phosphorylates the type I receptor. The type I receptor then phosphorylates receptorregulated Smads (R-Smads), which can now bind to the co-Smad, Smad4. R-Smad/co-Smad complexes accumulate in the nucleus where they act as transcription factors and participate in the regulation of target gene expression. Thus, Smad proteins are essential components of the intracellular signaling pathway activated by TGF-β1 in TGF-β1-induced fibrosis. Chen et al. (2011) investigated the effect of the overexpression of CYP2J2 epoxygenase on diabetic nephropathy in streptozotocininduced diabetic mice. They found that the overexpression of CYP2J2 attenuates Smad3 phosphorylation and increases the expression of Smad7. Kim et al. found that the loss of sEH (Kim et al. 2014) or the use of sEH inhibitor (Kim et al. 2015) promoted anti-inflammatory and fibroprotective effects in kidneys affected by unilateral ureteral obstruction via the activation of peroxisome proliferation-activated receptor (PPAR) isoforms and the downregulation of nuclear factor kappa B, TGF-β1/ Smad3 and the inflammatory signaling pathways. Thus, TPPU might inhibit TGF-β1-induced functional changes in mouse fibroblast by potentially regulating the TGF-β1/Smad3 and PPAR signaling pathways.
In summary, we found that TPPU attenuates BLM-induced pulmonary inflammation and fibrosis in the mouse in vivo and demonstrated that TPPU inhibits the proliferation, differentiation and collagen synthesis of mouse fibroblasts in vitro (Fig. 10) . TPPU inhibits the conversion of EETs to their diols and exerts anti-inflammatory and anti-fibrotic effects. The inhibition of sEH might be a novel approach for the treatment of PF. Fig. 10 Proposed mechanisms of the protective effect of TPPU on BLM-induced pulmonary fibrosis (EET epoxyeicosatrienoic acid, CYP450 cytochrome P450 epoxygenase, sEH soluble epoxide hydrolase, TPPU 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea, DHET dihydroxyeicosatrienoic acid)
